Literature DB >> 31718121

Analysis of the molecular subtypes of preoperative core needle biopsy and surgical specimens in invasive breast cancer.

Ye Sul Jeong1, Jun Kang1, Jieun Lee2,3, Tae-Kyung Yoo4, Sung Hun Kim5, Ahwon Lee1,3.   

Abstract

BACKGROUND: Accurate molecular classification of breast core needle biopsy (CNB) tissue is important for determining neoadjuvant systemic therapies for invasive breast cancer. The researchers aimed to evaluate the concordance rate (CR) of molecular subtypes between CNBs and surgical specimens.
METHODS: This study was conducted with invasive breast cancer patients who underwent surgery after CNB at Seoul St. Mary's Hospital between December 2014 and December 2017. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 were analyzed using immunohistochemistry. ER and PR were evaluated by Allred score (0-8). HER2 was graded from 0 to +3, and all 2+ cases were reflex tested with silver in situ hybridization. The labeling index of Ki67 was counted by either manual scoring or digital image analysis. Molecular subtypes were classified using the above surrogate markers.
RESULTS: In total, 629 patients were evaluated. The CRs of ER, PR, HER2, and Ki67 were 96.5% (kappa, 0.883; p<.001), 93.0% (kappa, 0.824; p<.001), 99.7% (kappa, 0.988; p<.001), and 78.7% (kappa, 0.577; p<.001), respectively. Digital image analysis of Ki67 in CNB showed better concordance with Ki67 in surgical specimens (CR, 82.3%; kappa, 0.639 for digital image analysis vs. CR, 76.2%; kappa, 0.534 for manual counting). The CRs of luminal A, luminal B, HER2, and triple negative types were 89.0%, 70.0%, 82.9%, and 77.2%, respectively.
CONCLUSIONS: CNB was reasonably accurate for determining ER, PR, HER2, Ki67, and molecular subtypes. Using digital image analysis for Ki67 in CNB produced more accurate molecular classifications.

Entities:  

Keywords:  Breast neoplasms; Core needle biopsy; Human epidermal growth factor receptor 2; Immunohistochemistry; Receptors, estrogen; Receptors, progesterone

Year:  2019        PMID: 31718121     DOI: 10.4132/jptm.2019.10.14

Source DB:  PubMed          Journal:  J Pathol Transl Med        ISSN: 2383-7837


  5 in total

1.  Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.

Authors:  Kristina A Tendl-Schulz; Fabian Rössler; Philipp Wimmer; Ulrike M Heber; Martina Mittlböck; Nicolas Kozakowski; Katja Pinker; Rupert Bartsch; Peter Dubsky; Florian Fitzal; Martin Filipits; Fanny Carolina Eckel; Eva-Maria Langthaler; Günther Steger; Michael Gnant; Christian F Singer; Thomas H Helbich; Zsuzsanna Bago-Horvath
Journal:  Virchows Arch       Date:  2020-05-07       Impact factor: 4.064

2.  What shear wave elastography parameter best differentiates breast cancer and predicts its histologic aggressiveness?

Authors:  Hyunjin Kim; Jeongmin Lee; Bong Joo Kang; Sung Hun Kim
Journal:  Ultrasonography       Date:  2020-06-15

3.  N-Cadherin Distinguishes Intrahepatic Cholangiocarcinoma from Liver Metastases of Ductal Adenocarcinoma of the Pancreas.

Authors:  Tiemo S Gerber; Benjamin Goeppert; Anne Hausen; Hagen R Witzel; Fabian Bartsch; Mario Schindeldecker; Lisa-Katharina Gröger; Dirk A Ridder; Oscar Cahyadi; Irene Esposito; Matthias M Gaida; Peter Schirmacher; Peter R Galle; Hauke Lang; Wilfried Roth; Beate K Straub
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

4.  Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients.

Authors:  Shuai Li; Xiaosong Chen; Kunwei Shen
Journal:  Front Surg       Date:  2022-06-28

5.  Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not.

Authors:  Young-Hoon Jeong; Soon Auck Hong; Hye Shin Ahn; Soo Kyung Ahn; Min Kyoon Kim
Journal:  J Cancer       Date:  2021-06-04       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.